Skip to Content

Brodalumab Approval Status

Brodalumab is a human anti-interleukin-17-receptor monoclonal antibody in development for the treatment of plaque psoriasis.

Development Status and FDA Approval Process for brodalumab

DateArticle
Jul 19, 2016FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque Psoriasis
Jan 26, 2016Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis
Sep  1, 2015AstraZeneca and Valeant Pharmaceuticals to Partner on Brodalumab
May 22, 2015Amgen to Terminate Participation in Co-Development and Commercialization of Brodalumab
Nov 25, 2014Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab
Nov 11, 2014Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide